Category: Guest content

How to Obtain Multiple Patent Term Extensions for a Single Product

The value of obtaining multiple PTEs on different patents could incentivize innovators to revise their clinical development programs This is a guest post from Nicole Stakleff and Kyle Dolinsky in…
The post How to Obtain Multiple Patent Term Extensions …


Data Exclusivity: Is there a happy medium?

What is Data Exclusivity? In 1984, the USA was the first country to give legal sanctity to data exclusivity via the Hatch-Waxman Act. Under this new legislation five years of…
The post Data Exclusivity: Is there a happy medium? appeared first on DrugPa…


Patent linkage: Balancing patent protection and generic entry

Patent linkage refers to the relationship between the market approval of a generic drug and the patent status of its branded equivalent. It dictates that marketing approval for a generic…
The post Patent linkage: Balancing patent protection and generic…


Are Generic Drugs Less Safe than their Branded Equivalents?

What are generic drugs? A generic drug is an identical, or bioequivalent, version of a branded drug made by another party. For approval of a generic, the drug company must…
The post Are Generic Drugs Less Safe than their Branded Equivalents? appeared f…


A Brief Patent Primer

… the very first official thing I did, in my administration … was to start a patent office; for I knew that a country without a patent office and good…
The post A Brief Patent Primer appeared first on DrugPatentWatch – Make Better Decisions.


Finding Generic Drug Entry Opportunities in Emerging Markets

Generic drugs present an opportunity for drug companies to generate substantial revenues. But where do companies find the best return for their investment of time and money? With mature markets…
The post Finding Generic Drug Entry Opportunities in Emer…


Pharma Starts a Feedback Loop

Billions are on the table for those who can break out of the mind rubble This is a guest post from John G. Singer. John is Director, Global Healthcare Strategy,…
The post Pharma Starts a Feedback Loop appeared first on DrugPatentWatch – Make Better Dec…


Biosimilar Naming: Distinguishable or Disingenuous?

This is a guest post from Robert Yapundich, MD and Gregory Schimizzi, MD. Dr. Yapundich is a practicing neurologist in Hickory, North Carolina and a member of the Alliance for…
The post Biosimilar Naming: Distinguishable or Disingenuous? appeared first…


DrugPatentWatch Guest Article Agreement

Thank you for your interest in submitting a guest article! Submit your guest article here DrugPatentWatch is interested in sharing and promoting content that is drug approvals, patent expirations, and…
The post DrugPatentWatch Guest Article Agreement a…


A Guide to Time Lag and Time Lag Shortening Strategies in Oncology-Based Drug Development

Transformation of a new scientific idea into a new oncology-based drug requires a tremendous amount of time, effort and investment. The initial, but critical first step in this process is transferring basic oncology research into a clinical application known as a “translational” or “bench to bedside study”. As a postdoctoral fellow who performs prostate cancer research related bench work, […]


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: